• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Multimarker assessment for the prediction of renal function improvement after percutaneous revascularization for renal artery stenosis.多标志物评估对预测经皮肾动脉狭窄血管重建术后肾功能改善的作用
Cardiovasc Diagn Ther. 2016 Jun;6(3):221-33. doi: 10.21037/cdt.2016.03.01.
2
Factors Associated with Outcomes of Percutaneous Transluminal Renal Angioplasty in Patients with Renal Artery Stenosis: A Retrospective Analysis of 50 Consecutive Cases.肾动脉狭窄患者经皮腔内肾血管成形术预后的相关因素:50例连续病例的回顾性分析
Int J Hypertens. 2018 Jan 4;2018:1952685. doi: 10.1155/2018/1952685. eCollection 2018.
3
Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.在粥样动脉硬化性肾动脉狭窄患者的支架血运重建术中进行线粒体保护(Elamipretide)的 2a 期临床试验。
Circ Cardiovasc Interv. 2017 Sep;10(9). doi: 10.1161/CIRCINTERVENTIONS.117.005487.
4
A study on the outcome of percutaneous transluminal renal angioplasty in patients with renal failure.一项关于肾衰竭患者经皮腔内肾血管成形术疗效的研究。
Nephron Clin Pract. 2006;104(3):c132-42. doi: 10.1159/000094916. Epub 2006 Aug 7.
5
Relationship between hemodynamic parameters of renal artery stenosis and the changes of kidney function after renal artery stenting in patients with hypertension and preserved renal function.高血压且肾功能正常患者肾动脉狭窄的血流动力学参数与肾动脉支架置入术后肾功能变化的关系
Blood Press. 2015 Feb;24(1):30-4. doi: 10.3109/08037051.2014.958304. Epub 2014 Sep 30.
6
Related factors for worsening renal function following percutaneous transluminal renal angioplasty (PTRA) in patients with atherosclerotic renal artery stenosis.经皮腔内肾血管成形术(PTRA)治疗粥样硬化性肾动脉狭窄患者肾功能恶化的相关因素。
Clin Exp Hypertens. 2015;37(7):526-30. doi: 10.3109/10641963.2015.1013125. Epub 2015 Apr 28.
7
Surgery after failed percutaneous renal artery angioplasty.经皮肾动脉血管成形术失败后的手术治疗。
J Vasc Surg. 1999 Sep;30(3):468-82. doi: 10.1016/s0741-5214(99)70074-1.
8
Plasma Renin Activity Predicts the Improvement in Resistant Hypertension after Percutaneous Transluminal Renal Artery Angioplasty.血浆肾素活性可预测经皮腔内肾动脉血管成形术后顽固性高血压的改善情况。
Intern Med. 2016;55(23):3421-3426. doi: 10.2169/internalmedicine.55.7312. Epub 2016 Dec 1.
9
Brain natriuretic peptides in atherosclerotic renal artery stenosis and effects of renal angioplasty.脑利钠肽在动脉粥样硬化性肾动脉狭窄中的作用及肾血管成形术的影响。
Kidney Blood Press Res. 2013;37(6):657-66. doi: 10.1159/000355746. Epub 2013 Dec 15.
10
Split renal function in patients with unilateral atherosclerotic renal artery stenosis-effect of renal angioplasty.单侧动脉粥样硬化性肾动脉狭窄患者的分肾功能——肾血管成形术的影响
Clin Kidney J. 2017 Aug;10(4):496-502. doi: 10.1093/ckj/sfx052. Epub 2017 Jul 3.

引用本文的文献

1
Non-invasive Stenotic Renal Artery Haemodynamics by Medicine.医学领域的无创性狭窄肾动脉血流动力学
Front Physiol. 2018 Aug 17;9:1106. doi: 10.3389/fphys.2018.01106. eCollection 2018.

本文引用的文献

1
Evidence based application of BNP/NT-proBNP testing in heart failure.BNP/NT-proBNP检测在心力衰竭中的循证应用
Clin Biochem. 2015 Mar;48(4-5):236-46. doi: 10.1016/j.clinbiochem.2014.11.002. Epub 2014 Nov 8.
2
Atherosclerotic renal artery stenosis and revascularization.动脉粥样硬化性肾动脉狭窄与血管重建术
Expert Rev Cardiovasc Ther. 2014 Dec;12(12):1419-25. doi: 10.1586/14779072.2014.977258. Epub 2014 Nov 5.
3
Where now in the management of renal artery stenosis? Implications of the ASTRAL and CORAL trials.肾动脉狭窄的治疗现状如何?ASTRAL和CORAL试验的启示。
Curr Opin Nephrol Hypertens. 2014 Nov;23(6):525-32. doi: 10.1097/MNH.0000000000000059.
4
Validity of estimated glomerular filtration rates for assessment of renal function after renal artery stenting in patients with atherosclerotic renal artery stenosis.估算肾小球滤过率评估动脉粥样硬化性肾动脉狭窄患者肾动脉支架置入术后肾功能的有效性。
JACC Cardiovasc Interv. 2014 May;7(5):543-9. doi: 10.1016/j.jcin.2013.11.021. Epub 2014 Apr 16.
5
Treatment of hypertension in patients with renal artery stenosis due to fibromuscular dysplasia of the renal arteries.肾动脉纤维肌性发育异常所致肾动脉狭窄患者的高血压治疗
Cardiovasc Diagn Ther. 2014 Feb;4(1):36-43. doi: 10.3978/j.issn.2223-3652.2014.02.01.
6
Renal artery stenosis: Up-date on diagnosis and treatment.肾动脉狭窄:诊断与治疗的最新进展
Vasa. 2014 Jan;43(1):27-38. doi: 10.1024/0301-1526/a000325.
7
Stenting and medical therapy for atherosclerotic renal-artery stenosis.经皮腔内血管成形术及药物治疗动脉粥样硬化性肾动脉狭窄
N Engl J Med. 2014 Jan 2;370(1):13-22. doi: 10.1056/NEJMoa1310753. Epub 2013 Nov 18.
8
Predictive value of renal resistive index in percutaneous renal interventions for atherosclerotic renal artery stenosis.肾阻力指数在经皮肾动脉介入治疗动脉粥样硬化性肾动脉狭窄中的预测价值。
J Invasive Cardiol. 2012 Oct;24(10):504-9.
9
Use of B-type natriuretic peptide to predict blood pressure improvement after percutaneous revascularisation for renal artery stenosis.应用 B 型利钠肽预测肾动脉狭窄经皮血管重建术后血压改善情况。
Eur J Vasc Endovasc Surg. 2010 Nov;40(5):599-607. doi: 10.1016/j.ejvs.2010.07.013. Epub 2010 Aug 23.
10
Mechanisms of tissue injury in renal artery stenosis: ischemia and beyond.肾动脉狭窄组织损伤的机制:缺血及其他。
Prog Cardiovasc Dis. 2009 Nov-Dec;52(3):196-203. doi: 10.1016/j.pcad.2009.09.002.

多标志物评估对预测经皮肾动脉狭窄血管重建术后肾功能改善的作用

Multimarker assessment for the prediction of renal function improvement after percutaneous revascularization for renal artery stenosis.

作者信息

Staub Daniel, Partovi Sasan, Zeller Thomas, Breidthardt Tobias, Kaech Max, Boeddinghaus Jasper, Puelacher Christian, Nestelberger Thomas, Aschwanden Markus, Mueller Christian

机构信息

1 Department of Angiology, University Hospital Basel, CH-4031 Basel, Switzerland ; 2 Department of Radiology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio, USA ; 3 Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany ; 4 Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, Basel, Switzerland.

出版信息

Cardiovasc Diagn Ther. 2016 Jun;6(3):221-33. doi: 10.21037/cdt.2016.03.01.

DOI:10.21037/cdt.2016.03.01
PMID:27280085
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4880754/
Abstract

BACKGROUND

Identifying patients likely to have improved renal function after percutaneous transluminal renal angioplasty and stenting (PTRA) for renal artery stenosis (RAS) is challenging. The purpose of this study was to use a comprehensive multimarker assessment to identify those patients who would benefit most from correction of RAS.

METHODS

In 127 patients with RAS and decreased renal function and/or hypertension referred for PTRA, quantification of hemodynamic cardiac stress using B-type natriuretic peptide (BNP), renal function using estimated glomerular filtration rate (eGFR), parenchymal renal damage using resistance index (RI), and systemic inflammation using C-reactive protein (CRP) were performed before intervention.

RESULTS

Predefined renal function improvement (increase in eGFR ≥10%) at 6 months occurred in 37% of patients. Prognostic accuracy as quantified by the area under the receiver-operating characteristics curve for the ability of BNP, eGFR, RI and CRP to predict renal function improvement were 0.59 (95% CI, 0.48-0.70), 0.71 (95% CI, 0.61-0.81), 0.52 (95% CI, 0.41-0.65), and 0.56 (95% CI, 0.44-0.68), respectively. None of the possible combinations increased the accuracy provided by eGFR (lower eGFR indicated a higher likelihood for eGFR improvement after PTRA, P=ns for all). In the subgroup of 56 patients with pre-interventional eGFR <60 mL/min/1.73 m(2), similar findings were obtained.

CONCLUSIONS

Quantification of renal function, but not any other pathophysiologic signal, provides at least moderate accuracy in the identification of patients with RAS in whom PTRA will improve renal function.

摘要

背景

对于因肾动脉狭窄(RAS)而行经皮腔内肾血管成形术和支架置入术(PTRA)的患者,识别哪些患者肾功能可能改善具有挑战性。本研究的目的是使用全面的多标志物评估来识别那些将从纠正RAS中获益最大的患者。

方法

在127例因RAS且肾功能下降和/或高血压而转诊接受PTRA的患者中,在干预前使用B型利钠肽(BNP)对血流动力学心脏应激进行量化,使用估计肾小球滤过率(eGFR)评估肾功能,使用阻力指数(RI)评估肾实质损伤,使用C反应蛋白(CRP)评估全身炎症。

结果

6个月时预定义的肾功能改善(eGFR增加≥10%)发生在37%的患者中。BNP、eGFR、RI和CRP预测肾功能改善能力的受试者操作特征曲线下面积所量化的预后准确性分别为0.59(95%CI,0.48 - 0.70)、0.71(95%CI,0.61 - 0.81)、0.52(95%CI,0.41 - 0.65)和0.56(95%CI,0.44 - 0.68)。没有任何一种可能的组合能提高eGFR所提供的准确性(较低的eGFR表明PTRA后eGFR改善的可能性更高,所有P值均无统计学意义)。在干预前eGFR<60 mL/min/1.73 m²的56例患者亚组中,获得了类似的结果。

结论

肾功能的量化而非任何其他病理生理信号,在识别PTRA可改善肾功能的RAS患者中至少提供了中等程度的准确性。